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Objectives: To investigate in vivo degeneration of the cholinergic system in mild cognitive impairment with Lewy 
bodies (MCI-LB), we studied nucleus basalis of Meynert (NBM) volumes from structural MR images and its 
relation to EEG slowing and cognitive impairment. 
Methods: We studied the NBM using structural MR images in 37 patients with MCI-LB, 34 patients with MCI with 
Alzheimer’s disease (MCI-AD), and 31 healthy control participants. We also tested correlations between NBM 
volumes and measures of overall cognition and measures of EEG slowing in the MCI groups. 
Results: Overall NBM volume was reduced in MCI-LB compared to controls with no significant difference between 
MCI-AD and controls or between the two MCI groups. The voxel-wise analysis revealed bilateral clusters of 
reduced NBM volume in MCI-LB compared to controls and smaller clusters in MCI-AD compared to controls. 
There was a significant association between overall NBM volume and measures of overall cognition in MCI-LB, 
but not in MCI-AD. In both MCI groups, reduced NBM volume was correlated with more severe EEG slowing. 
Conclusions: This study provides in vivo evidence that early cholinergic degeneration in DLB occurs at the MCI 
stage and is related to the severity of cognitive impairment. Furthermore, the results suggest that early EEG 
slowing in MCI-LB might be in part cholinergically driven. Importantly, these findings suggest an early cholin-
ergic deficit in MCI-LB that may motivate further testing of the effectiveness of cholinesterase inhibitors in this 
group.   
1. Introduction 
Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) are 
characterized by marked cholinergic deficits (Lippa et al., 1999; Tira-
boschi et al., 2002) which have been shown to be more severe in DLB 
compared to AD (Colloby et al., 2017; Hanyu et al., 2007; Kim et al., 
2011; Whitwell et al., 2007) and are mainly caused by degeneration of 
the nucleus basalis of Meynert (NBM) (Erskine et al., 2019; Lippa et al., 
1999; Perry et al., 1993). DLB is frequently preceded by a period of mild 
cognitive impairment (MCI) in which cognitive decline is present, but 
independence in activities of daily living is preserved (Donaghy et al., 
2018; McKeith et al., 2020). In patients with Parkinson’s disease and AD, 
NBM degeneration occurs early and smaller NBM volumes are predictive 
of future cognitive impairment (Grothe et al., 2013, 2012; Ray et al., 
2018; Schulz et al., 2018; Teipel et al., 2018, 2011). While post-mortem 
studies suggest that cholinergic deficits in DLB might occur earlier in the 
course of the disease compared to AD (Tiraboschi et al., 2002), no 
previous study has investigated early cholinergic changes in DLB in vivo 
and how these relate to cognitive impairment in patients with MCI with 
Lewy bodies (MCI-LB). The first aim of this study was therefore to 
investigate NBM volumes in MCI-LB compared to healthy controls and 
MCI with Alzheimer’s disease (MCI-AD) and the relationship with 
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cognitive impairment in the MCI groups. 
Quantitative EEG shows a slowing of the EEG rhythm in MCI-LB 
patients (Bonanni et al., 2015; van der Zande et al., 2020; Schumacher 
et al., 2020a). However, while early EEG abnormalities seem to be 
specific to Lewy body disease – they are much less severe in patients 
with MCI-AD – these changes are not observed in all MCI-LB patients 
(Schumacher et al., 2020a). The reason for this heterogeneity in EEG 
measures across patients is unclear and it is not clear what causes early 
EEG changes in MCI-LB. However, it has been suggested that EEG 
slowing in dementia patients might be related to cholinergic deficits 
(Adler et al., 2004; Babiloni et al., 2013; Riekkinen et al., 1991). 
Furthermore, we recently identified a relationship between a loss of EEG 
alpha reactivity and reduced NBM volumes in patients with Parkinson’s 
disease dementia (Schumacher et al., 2020b). The second aim of this 
study was therefore to investigate whether early changes in quantitative 
EEG measures – including measures of EEG slowing and alpha reactivity 
– are related to early NBM degeneration in MCI-LB. 
2. Materials and methods 
2.1. Participants 
This study included 102 participants who were over 60 years of age. 
Recruitment and clinical assessment have been described previously 
(Schumacher et al., 2020a). Briefly, patients were recruited from local 
memory services and MCI diagnoses were made by a consensus panel of 
three experienced old-age psychiatrists according to NIA-AA criteria 
(Albert et al., 2011). In addition to a detailed clinical assessment, par-
ticipants had already undergone dopaminergic imaging with 123I-N- 
fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl) single-photon emis-
sion computed tomography (FP-CIT SPECT) and 123iodine-meta-
iodobenzylguanidine (MIBG) myocardial scintigraphy through their 
involvement in an ongoing study investigating the diagnostic accuracy 
of imaging biomarkers in MCI and this information was used to apply 
diagnostic criteria (see below). All patients had a CDR of 0 or 0.5 and 
patients with a diagnosis of dementia or subjective cognitive impair-
ment only were excluded. 
The presence/absence of the core Lewy body symptoms (visual 
hallucinations, cognitive fluctuations, Parkinsonism, and REM sleep 
behaviour disorder) was rated by the panel utilizing the rating scales and 
all information from the clinical assessments (McKeith et al., 2017). A 
diagnosis of MCI with probable Alzheimer’s disease (MCI-AD) was given 
to patients who had no core Lewy body symptoms, negative FP-CIT and 
MIBG findings, and evidence of cognitive decline that was characteristic 
of AD, i.e. they met the additional NIA-AA criterion for “aetiology of MCI 
consistent with AD pathophysiologic process”. Probable MCI with Lewy 
bodies (MCI-LB) was diagnosed if a patient had two or more core Lewy 
body symptoms or one core symptom in addition to a positive FP-CIT 
and/or MIBG scan (McKeith et al., 2020). 
According to these criteria, 37 participants were diagnosed with 
probable MCI-LB and 34 were diagnosed with MCI-AD. Eighteen MCI 
participants who were diagnosed with possible MCI-LB (i.e. only one 
core Lewy body symptom or a positive FP-CIT or MIBG scan) were 
excluded from the present analysis. Healthy controls (N = 31) were 
recruited from friends and relatives of the patients and from a local 
research register and had no history of psychiatric or neurological 
illness, no evidence of cognitive decline, and normal MR scans. 
Written informed consent was obtained from all participants and the 
study was approved by the Newcastle & North Tyneside 2 Research 
Ethics Committee. 
2.2. EEG acquisition and preprocessing 
The resting state EEG protocol has been described before (Schu-
macher et al., 2020a). Briefly, 300 s of resting state eyes-closed EEG data 
followed by 300 s of resting state eyes-open EEG data were recorded 
using Waveguard caps (ANT Neuro) comprising 128 electrodes. 
Preprocessing of eyes-closed and eyes-open EEG data was performed 
using the EEGLAB toolbox (version 14) in Matlab (R2017a) and included 
bandpass-filtering between 0.3 and 54 Hz, creating non-overlapping 
epochs of 2 s, visually inspecting the data, and exclusion of noisy 
channels and epochs (mean (standard deviation) number of excluded 
channels, HC: 6.4 (2.8), MCI-AD: 8.3 (4.1), MCI-LB: 6.5 (3.2)) (Schu-
macher et al., 2020a). Subsequently, independent component analysis 
was applied and components representing muscular, cardiac, ocular, or 
electrical (50 Hz line noise) artefacts were rejected. Previously excluded 
channels were replaced using spherical spline interpolation and data 
were average referenced. For each participant, the first 45 2-second long 
artefact-free epochs of eyes-closed and the first 45 2-second long epochs 
of eyes-open EEG data were selected for analysis. 
2.3. Quantitative analysis of eyes-closed EEG data 
The quantitative EEG analysis for eyes-closed data has been detailed 
previously (Schumacher et al., 2020a). Briefly, the power spectral den-
sity (PSD) was estimated for each 2-second epoch and mean power 
across all included epochs was estimated for different standard EEG 
frequency bands including delta (2–4 Hz), theta (4–5.5 Hz), pre-alpha 
(5.5–8 Hz), alpha (8–13 Hz), and beta (13–30 Hz). The pre-alpha band 
was included based on previous studies in DLB (Bonanni et al., 2008). 
The PSD within each frequency band was normalized by the total power 
across the power spectrum. The dominant frequency (DF) was calculated 
as the frequency with the highest power between 4 and 15 Hz (averaged 
across epochs). Dominant frequency was calculated for all electrodes as 
well as from occipital electrodes only (PO9, PO7, POO9h, PO5, O1, PO3, 
POO3h, OI1h, POz, Oz, PO4, POO4h, PO6, O2, OI2h, PO8, POO10h, 
PO10). Results from this analysis have been reported previously 
(Schumacher et al., 2020a). 
2.4. EEG alpha reactivity analysis 
EEG data from three occipital electrodes (O1, O2, and Oz) were used 
for the alpha reactivity analysis (Schumacher et al., 2020b; Wan et al., 
2019). The PSD for the three electrodes was averaged across all included 
epochs and across the three electrodes for each condition separately 
(eyes-open and eyes-closed). 
Alpha reactivity was calculated according to the following formula 
(Wan et al., 2019): 
alpha reactivity =
alpha power eyes closed − alpha power eyes open
alpha power eyes closed  
where alpha power was computed as the relative power within a fre-
quency bin around the individual alpha peak frequency ±2 Hz. Indi-
vidual alpha peak frequencies were calculated by locating the peak in 
the PSD in the extended alpha frequency band from 4 to 14 Hz (Babiloni 
et al., 2017, 2011) using the eyes-closed data. Individual alpha peak 
frequencies were used instead of the standard alpha frequency band to 
account for a shift of the alpha peak to slower frequencies in MCI pa-
tients (Bonanni et al., 2015; Schumacher et al., 2020a). 
2.5. MRI acquisition and preprocessing 
MR images were acquired on a 3T Philips Intera Achieva scanner 
with a magnetisation prepared rapid gradient echo (MPRAGE) 
sequence, sagittal acquisition, echo time 4.6 ms, repetition time 8.3 ms, 
inversion time 1250 ms, flip angle = 8◦, SENSE factor = 2, and in-plane 
field of view 216 × 240 mm2 with slice thickness 1.0 mm, yielding a 
voxel size of 1.0 × 1.0 × 1.0 mm3. 
Preprocessing of MR images was performed in SPM12 (http://www. 
fil.ion.ucl.ac.uk/spm/). Images were first segmented into grey matter, 
white matter, and cerebrospinal fluid. The DARTEL algorithm 
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(Ashburner, 2007) was used to create a study-specific template and all 
grey matter images were coregistered to this template. As a final step, 
images were smoothed with a 4 mm full width at half maximum 
Gaussian kernel. 
2.6. NBM volume analysis 
The NBM forms part of the basal forebrain which consists of 
cholinergic cells that can be histologically defined as Ch1-Ch6 where 
Ch4 corresponds to the NBM (Mesulam et al., 1983). A region of interest 
mask of the NBM (see Fig. 1A) was created using a probabilistic 
anatomical map from the SPM Anatomy Toolbox (Eickhoff et al., 2005) 
which is based on microscopic delineations of ten post-mortem human 
brains (Zaborszky et al., 2008). The mask consisted of 71 voxels for the 
left NBM and 59 voxels for the right NBM. To transform the NBM mask 
from MNI standard space to the study-specific template space, we used 
Advanced Normalization Tools (Avants et al., 2011; Klein et al., 2009) to 
affine register the study-specific DARTEL template to MNI space and 
applied the inverse transform to the NBM map. 
For each participant, using the unsmoothed grey matter images, grey 
matter volume within the NBM mask was calculated and averaged 
across right and left hemispheres. Total intracranial volume was calcu-
lated in SPM and was used to normalise NBM volumes using propor-
tional normalisation. 
2.7. Statistics 
EEG alpha reactivity and overall NBM volume were compared be-
tween the groups using univariate ANOVAs including covariates for age 
and sex. This was followed by post-hoc tests which were Bonferroni- 
corrected for multiple comparisons. 
In addition to investigating overall NBM volumes, we also conducted 
a voxel-wise group comparison of volumes within the NBM mask by 
running a voxel-based morphometry (VBM) analysis in SPM using the 
smoothed grey matter images. We included covariates for age, sex, and 
total intracranial volume. The statistical threshold was set at p < 0.05, 
family wise error (FWE)-corrected for multiple comparisons. 
In the MCI-AD and MCI-LB groups separately, Spearman’s correla-
tions were calculated between the different EEG characteristics and 
overall NBM volume. Additionally, the association between NBM vol-
ume and the Mini Mental State Examination (MMSE) and Adden-
brooke’s Cognitive Examination - Revised (ACE-R) as measures of global 
Fig. 1. NBM region of interest and group comparisons. A) NBM mask overlaid on the study-specific DARTEL grey matter template. B) Comparison of alpha reactivity 
between groups. C) Comparison of overall NBM volume between groups. HC, healthy controls; MCI-AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, 
mild cognitive impairment with Lewy bodies; NBM, nucleus basalis of Meynert. 
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cognitive impairment were assessed using Spearman’s correlations in 
the two MCI groups separately. All p-values from the correlation ana-
lyses were false discovery rate (FDR)-corrected for multiple 
comparisons. 
Furthermore, the MCI-LB group was dichotomized with respect to 
the presence (N = 17) vs absence (N = 19) of treatment with cholines-
terase inhibitors, and NBM volumes were compared between the sub-
groups using two-sample t-tests. 
3. Results 
3.1. Demographics 
All three groups were similar in age and the two MCI groups were 
similar in terms of global cognitive impairment (Table 1). There were 
more male participants in the MCI-LB group whereas the MCI-AD group 
involved more female participants. As expected, the MCI-LB group had 
more Parkinsonism, and higher cognitive fluctuation and visual hallu-
cination scores compared to the MCI-AD group and more MCI-LB par-
ticipants were taking cholinesterase inhibitors and Parkinson’s 
medication. 
3.2. EEG frequency analysis 
The results of the frequency analysis have been reported previously 
(Schumacher et al., 2020a). In summary, there was a general slowing of 
the EEG in MCI-LB patients compared to healthy controls and MCI-AD by 
a shift in power from beta and alpha frequency bands towards slower 
frequencies in the pre-alpha and theta range. This was also reflected by a 
shift of the dominant frequency towards slower frequencies in the MCI- 
LB group compared to MCI-AD and controls. 
3.3. EEG alpha reactivity analysis 
Two control participants, three MCI-AD, and one MCI-LB patient had 
to be excluded from the alpha reactivity analysis because their eyes- 
open EEG data were too noisy. The alpha reactivity analysis therefore 
included 29 controls, 31 MCI-AD, and 36 MCI-LB participants. 
There was an overall effect of diagnosis on alpha reactivity (F(2,91) 
= 11.2, p < 0.001, Fig. 1B). Post-hoc tests showed that alpha reactivity 
was significantly reduced in MCI-AD compared to controls (p < 0.001) 
and in MCI-LB compared to controls (p = 0.008) whereas there was no 
significant difference between the two MCI groups (p = 0.30). 
3.4. NBM volume analysis 
The ANOVA showed an effect of diagnosis on overall NBM volume (F 
(2,97) = 4.2, p = 0.02). Post-hoc tests revealed that overall NBM vol-
umes were significantly reduced in the MCI-LB group compared to 
controls (p = 0.01) with no significant difference between MCI-AD and 
controls (p = 0.49) or between the two MCI groups (p = 0.53, Fig. 1C). 
Including a covariate for cholinesterase inhibitor use did not change 
the results: F(2,92) = 4.4, p = 0.02; p(HC,MCI-AD) = 0.66, p(HC,MCI- 
LB) = 0.01, p(MCI-AD,MCI-LB) = 0.26. 
The voxel-wise analysis revealed a bilateral reduction in NBM vol-
ume in the MCI-LB group compared to controls (Table 2, Fig. 2A), with 
about 27% of the right and 17% of the left NBM showing more severe 
atrophy in the MCI-LB group compared to controls. Smaller clusters of 
reduced NBM volume in the MCI-AD group compared to controls were 
found bilaterally (Table 2, Fig. 2B), with about 8% of the left NBM and 
about 7% of the right NBM showing more severe atrophy in MCI-AD 
compared to controls. There were no significant clusters with 
increased NBM volume in either MCI group compared to controls and no 
significant differences in the direct comparison between MCI-AD and 
MCI-LB. The results from the comparison of the two MCI groups did not 
change when including a covariate for the use of cholinesterase 
inhibitors. 
3.5. Association between EEG measures and NBM volume 
In the MCI-LB group, theta and pre-alpha power and the theta/alpha 
ratio were negatively and alpha and beta power were positively corre-
lated with overall NBM volume (Table 3 and Fig. 3A). Furthermore, 
dominant frequency was positively correlated with NBM volume. In the 
MCI-AD group, theta power and the theta/alpha ratio were negatively 
correlated with NBM volume whereas alpha power and dominant 
Table 1 


















76.3 (7.6) 74.7 (6.5) F(2,99) = 1.1, p =
0.33b 
AChEI – 6 (18%)e 17 (46%)f χ2 = 6.1, p = 0.01c 















82.3 (8.7) 83.5 (9.3) t69 = 0.6, p = 0.58d 
MMSE 28.5 
(1.1) 
26.9 (2.2) 26.5 (2.5) t69 = 0.9, p = 0.39d 
UPDRS III 5.5 (4.4) 15.7 (14.0) 23.5 (14.5) t69 = 2.3, p = 0.02d 
DCFS – 6.9 (1.9)i 8.4 (3.3)k t59 = 2.2, p = 0.03d 
CAF total – 1.4 (2.7)i 3.8 (4.3)k t59 = 2.5, p = 0.01d 
NPI total – 8.6 (9.3)i 16.1 (13.1)k t59 = 2.5, p = 0.02d 
NEVHI – 0.8 (1.6)e 2.9 (4.2) t67 = 2.6, p = 0.01d 
ACE-R, Addenbrooke’s Cognitive Examination – Revised; AChEI, number of 
patients taking acetylcholinesterase inhibitors; CAF total, Clinician Assessment 
of Fluctuation total score; DCFS, Dementia Cognitive Fluctuation Scale; HC, 
healthy controls; MCI-AD, mild cognitive impairment with Alzheimer’s disease; 
MCI-LB, mild cognitive impairment with Lewy bodies; MMSE, Mini Mental State 
Examination; NEVHI, North-East Visual Hallucinations Interview; NPI, Neuro-
psychiatric Inventory; PD meds, number of patients taking dopaminergic 
medication for the management of Parkinson’s disease symptoms; UPDRS III, 
Unified Parkinson’s Disease Rating Scale III (motor subsection) 
a Chi-square test HC, MCI-AD, MCI-LB; b Univariate ANOVA HC, MCI-AD, 
MCI-LB; c Chi-square test MCI-AD, MCI-LB; d Student’s t-test MCI-AD, MCI-LB. 
e N = 32, f N = 36, g N = 29, h N = 33, i N = 27, k N = 34 
Table 2 
Significant clusters (pFWE < 0.05) from voxel-based morphometry analysis. 
Cluster size is given in voxels. There were no significant clusters for the other 
contrasts (MCI-AD > HC and MCI-LB > HC) or for the comparison between the 
two MCI groups.   
cluster size T p (FWE) location 
HC > MCI-AD  
4  3.51  0.042 right NBM  
5  3.39  0.039 left NBM  
HC > MCI-LB  
13  3.79  0.032 right NBM  
9  3.77  0.037 left NBM  
3  3.34  0.037 right NBM  
3  3.32  0.042 left NBM  
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frequency were positively correlated with NBM volume (Table 3 and 
Fig. 3B). There was no significant correlation between NBM volume and 
alpha reactivity in either group. 
3.6. Clinical correlations 
In MCI-LB, NBM volume was positively correlated with the MMSE 
score and with the ACE-R whereas there were no significant correlations 
in the MCI-AD group between NBM volume and MMSE or ACE-R scores 
(Table 3 and Fig. 3). 
There were no differences between MCI-LB patients who were taking 
cholinesterase inhibitors compared to those who were not in terms of 
overall NBM volume (t34 = 0.57, p = 0.57). 
4. Discussion 
In this study, we showed that atrophy of the NBM in MCI-LB is 
greater than normal age-related volume loss and occurs bilaterally with 
about 20% of the NBM showing significantly more severe atrophy 
compared to controls. Previous studies have reported degeneration of 
the NBM in DLB patients at the dementia stage (Colloby et al., 2017; 
Hanyu et al., 2007; Kim et al., 2011; Whitwell et al., 2007) and findings 
from a post-mortem study have suggested that cholinergic deficits might 
occur early in the course of the disease (Tiraboschi et al., 2002). The 
results of the present study support this finding by providing in vivo 
evidence of early cholinergic system alterations in DLB. 
In MCI-AD, while overall NBM volumes were not significantly 
different from healthy controls, the voxel-wise analysis revealed atrophy 
in similar locations as in the MCI-LB group, albeit with smaller spatial 
extent. This is in line with previous studies that have reported degen-
eration of the NBM in MCI-AD compared to healthy controls (Grothe 
et al., 2013, 2012; Teipel et al., 2011). 
While the direct comparison between the MCI groups did not reveal 
significant differences, the voxel-wise comparison with healthy control 
volumes suggests that the spatial extent of NBM atrophy in MCI-LB 
might be greater than in MCI-AD. This would be in line with previous 
reports of more severe structural abnormalities within the cholinergic 
system in DLB compared to AD (Colloby et al., 2017; Hanyu et al., 2007, 
2005; Kim et al., 2011; Tiraboschi et al., 2002; Whitwell et al., 2007) and 
provides tentative indication that this difference might already be 
evident in early stages of the disease. 
Reduced NBM volumes were correlated with more severe EEG 
slowing in both MCI groups, suggesting that the cholinergic system 
might have an influence on the resting state cortical EEG signal in MCI 
patients. In the MCI-LB group, a greater shift of power towards slower 
frequencies and a more severe slowing of the dominant EEG rhythm 
were related to more severe NBM degeneration whereas in the MCI-AD 
group, this relationship was mainly restricted to the dominant EEG 
rhythm. These results are in line with previous studies at the dementia 
stage suggesting that EEG slowing in dementia patients might be related 
to cholinergic degeneration (Adler et al., 2004; Babiloni et al., 2013; 
Riekkinen et al., 1991). Our study suggests that this relationship is 
already evident in patients at the MCI stage. While early EEG slowing 
shows relatively high specificity for MCI-LB over MCI-AD, a significant 
number of MCI-LB patients still exhibit EEG patterns which are similar to 
healthy control and MCI-AD levels (Schumacher et al., 2020a). The 
present results indicate that the level of cholinergic degeneration might 
play a role in explaining this heterogeneity, suggesting that MCI-LB 
patients with less early NBM atrophy might show fewer abnormalities 
in quantitative EEG measures. 
EEG alpha reactivity which has been suggested as a marker of 
cholinergic system integrity (Osipova et al., 2003; Wan et al., 2019) was 
not related to NBM volumes in either MCI group. This is in line with our 
previous investigation of alpha reactivity in dementia patients where we 
found an association with NBM volumes only in patients with Parkin-
son’s disease dementia, but not in AD or DLB (Schumacher et al., 
2020b). Patients with an initial presentation of Parkinsonism were 
excluded from the present study. Our results therefore further support 
the finding that NBM degeneration does not seem to be related to a loss 
of alpha reactivity in AD or DLB patients. 
Fig. 2. Voxel-based comparison of NBM volumes. A) Significant clusters within 
the NBM mask for the contrast HC > MCI-AD. B) Significant clusters within the 
NBM mask for the contrast HC > MCI-LB. The NBM mask is shown in blue and 
significant voxels are shown in red. See Table 2 for statistics of significant 
clusters. (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) HC, healthy controls; MCI- 
AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, mild cogni-
tive impairment with Lewy bodies; NBM, nucleus basalis of Meynert 
Table 3 
Spearman’s correlations between different quantitative EEG characteristics, 
cognitive variables, and mean NBM volume in MCI-AD and MCI-LB. P-values are 
FDR-corrected for multiple comparisons.   
MCI-AD MCI-LB 
Delta power ρ = − 0.27, p = 0.15 ρ = − 0.29, p = 0.12 
Theta power ρ = − 0.41, p = 0.03 ρ = − 0.44, p = 0.01 
Pre-alpha power ρ = − 0.27, p = 0.15 ρ = − 0.56, p = 0.003 
Alpha power ρ = 0.38, p = 0.04 ρ = 0.45, p = 0.01 
Beta power ρ = 0.08, p = 0.63 ρ = 0.56, p = 0.003 
Theta/alpha ratio ρ = − 0.48, p = 0.01 ρ = − 0.49, p = 0.007 
DF, all electrodes ρ = 0.54, p = 0.005 ρ = 0.51, p = 0.005 
DF, occipital electrodes ρ = 0.51, p = 0.007 ρ = 0.60, p = 0.002 
Alpha reactivity ρ = 0.13, p = 0.51 ρ = 0.31, p = 0.10 
ACE-R ρ = 0.26, p = 0.17 ρ = 0.44, p = 0.01 
MMSE ρ = 0.20, p = 0.28 ρ = 0.41, p = 0.02 
ACE-R, Addenbrooke’s Cognitive Examination – Revised; DF, dominant fre-
quency; MCI-AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, 
mild cognitive impairment with Lewy bodies; MMSE, Mini-Mental State 
Examination 
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Smaller NBM volumes were related to more severe cognitive 
impairment in MCI-LB whereas there was no significant association 
between cognitive impairment and NBM volumes in the MCI-AD group. 
This suggests that the early cholinergic deficit observed in MCI-LB might 
be more directly and more strongly related to cognitive impairment 
whereas in MCI-AD there might be additional factors that are driving 
cognitive impairment at this disease stage, such as neurodegeneration of 
the medial temporal lobe (Kantarci et al., 2016; Mak et al., 2016). In 
turn, this also suggests that cholinergic remediation might provide a 
larger improvement in cognitive function in MCI-LB patients, and that 
EEG may help to stratify those patients who might respond to treatment 
at this early stage. 
A potential limitation of the present study is the use of cholinesterase 
inhibitors in the MCI patients and more MCI-LB patients were taking 
these medications compared to the MCI-AD group which might have 
influenced group comparisons of NBM volumes or EEG measures (Gia-
notti et al., 2008). Such prescribing reflects local use for neuropsychi-
atric symptoms in Lewy body diseases and is in line with recent advice 
(Taylor et al., 2020). However, we did not find differences in NBM 
volumes between MCI-LB patients who were taking cholinesterase in-
hibitors compared to those patients not taking these medications and 
including cholinesterase inhibitor use as a covariate in the group com-
parisons did not change the results. Similarly, when previously 
comparing MCI patients who were taking cholinesterase inhibitors to 
those who were not, we did not find any significant differences in any 
EEG measures (Schumacher et al., 2020a). However, investigating the 
prospective effect of cholinesterase inhibitor treatment on NBM volumes 
in MCI-LB patients in more detail will be an interesting avenue for future 
research (Cavedo et al., 2017). Four patients from the MCI-LB group 
were also taking dopaminergic medication for the management of 
Fig. 3. Relationship between NBM volume and EEG slowing and cognitive impairment. Correlations between NBM volume and EEG and cognitive measures in A) 
MCI-LB and B) MCI-AD. All p-values are FDR-corrected for multiple comparisons. ACE-R, Addenbrooke’s Cognitive Examination – Revised; DF, dominant frequency; 
MCI-AD, mild cognitive impairment with Alzheimer’s disease; MCI-LB, mild cognitive impairment with Lewy bodies; MMSE, Mini-Mental State Examination; NBM, 
nucleus basalis of Meynert. 
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Parkinson’s disease symptoms (three patients were taking Carbidopa- 
Levodopa and one patient was taking Rotigotine). However, the small 
number of patients taking these medications did not allow for a more in- 
depth analysis of the effect of dopaminergic medication on cognition, 
NBM volumes or EEG measures (Babiloni et al., 2019); this remains a 
limitation of this work. 
Another possible limitation is the fact that the majority of our MCI- 
LB patients were male while the male/female ratio was more balanced 
in the MCI-AD group. This might have influenced our results given that 
there is some evidence for sex differences in NBM structure (Amunts, 
2007). Sex imbalances are an inherent problem of many AD/DLB com-
parison studies due to the higher prevalence of DLB in men and AD in 
women, respectively (Beam et al., 2018; Savica et al., 2013). To mini-
mise the impact of these group imbalances on our results, we have 
included a covariate for sex in all analyses. Nevertheless, studying the 
influence of sex on NBM degeneration in MCI patients will be an 
important step in future studies. 
In conclusion, this study provides in vivo insight into early patho-
physiology in Lewy body disease by suggesting that early degeneration 
of the cholinergic system occurs in MCI-LB patients and is related to the 
severity of cognitive impairment. Furthermore, the results suggest that 
early EEG slowing in MCI patients might be cholinergically driven and 
that differences in the level of cholinergic deficits might explain het-
erogeneity with respect to EEG findings in MCI-LB patients. Importantly, 
these findings suggest that the cholinergic system is affected early in 
MCI-LB and thus underline the potential effectiveness of early treatment 
with cholinesterase inhibitors in these patients. 
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